ALKS logo

Alkermes (ALKS) Stock

Profile

Sector:

Healthcare

Country:

Ireland

IPO:

16 July 1991

Indexes:

Not included

Description:

Alkermes is a biopharmaceutical company that develops innovative medicines for mental health and addiction. They focus on creating treatments for conditions like schizophrenia, depression, and opioid dependence, aiming to improve patients' lives through effective therapies and advanced drug delivery systems.

Key Details

Price

$30.00

Annual Revenue

$1.66 B(+49.61% YoY)

Annual EPS

$2.10(+316.49% YoY)

PE Ratio

15.38(-30.03% YoY)

Beta

0.58

Events Calendar

Earnings

Next earnings date:

Feb 14, 2025

Recent quarterly earnings:

Oct 24, 2024

Recent annual earnings:

Feb 15, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

May 15, 2000

Analyst ratings

Recent major analysts updates

13 Nov '24 Mizuho
Outperform
05 Nov '24 Stifel
Buy
25 Oct '24 Piper Sandler
Overweight
25 Oct '24 JP Morgan
Neutral
25 Oct '24 HC Wainwright & Co.
Neutral
25 Oct '24 Goldman Sachs
Buy
25 Oct '24 Cantor Fitzgerald
Overweight
14 Oct '24 HC Wainwright & Co.
Neutral
10 Oct '24 Cantor Fitzgerald
Overweight
16 Sept '24 Cantor Fitzgerald
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Alkermes to Participate in Upcoming Investor Conferences
Alkermes to Participate in Upcoming Investor Conferences
Alkermes to Participate in Upcoming Investor Conferences
ALKS
prnewswire.com25 November 2024

DUBLIN, Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has announced that its management will take part in two investor conferences soon. The 7th Annual Evercore ISI HealthCONx Conference is scheduled for Tuesday, Dec. 3, 2024, at 10:25 a.m.

Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
ALKS
seekingalpha.com24 November 2024

Alkermes has moved from earning money through royalties to selling its own products, thanks to the success of Lybalvi, Vivitrol, and Aristada. The company’s ALKS 2680, which is in Phase 2 trials for treating narcolepsy and hypersomnia, could be a game-changer in a market expected to reach $7.3 billion by 2032. With $908.9 million in available funds and a positive cash flow of $73.3 million in the third quarter, Alkermes is well-positioned to support its research and development as well as its operations.

Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
ALKS
zacks.com25 October 2024

ALKS has announced that its results for the third quarter of 2024 were not as strong as anticipated. However, the net sales of its own products have risen compared to the previous year.

Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript
Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript
Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript
ALKS
seekingalpha.com24 October 2024

Alkermes plc (NASDAQ:ALKS) will hold its Q3 2024 Earnings Conference Call on October 24, 2024, at 8:00 AM ET. The call will feature company representatives including Sandra Coombs, Richard Pops, Todd Nichols, and Blair Jackson. Various analysts from firms like TD Cowen, Evercore, and JPMorgan will also participate in the call.

Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
ALKS
zacks.com24 October 2024

Alkermes (ALKS) reported quarterly earnings of $0.73 per share, which is lower than the Zacks Consensus Estimate of $0.78 per share. This is an increase from the earnings of $0.64 per share from the same period last year.

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
ALKS
zacks.com24 October 2024

The main figures for Alkermes (ALKS) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be useful to look at some of its important metrics in relation to Wall Street predictions and the results from the same period last year.

Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
ALKS
zacks.com22 October 2024

In addition to Wall Street's predictions for Alkermes' (ALKS) earnings, take a look at forecasts for some important metrics to better understand how the company performed in the quarter that ended in September 2024.

Here's Why Alkermes (ALKS) is a Strong Growth Stock
Here's Why Alkermes (ALKS) is a Strong Growth Stock
Here's Why Alkermes (ALKS) is a Strong Growth Stock
ALKS
zacks.com10 October 2024

Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
ALKS
prnewswire.com25 September 2024

DUBLIN, Sept. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has announced that it will hold an investor event for financial analysts and institutional investors on Wednesday, October 9, 2024, beginning at 10:00 a.m.

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
ALKS
prnewswire.com23 September 2024

Alkermes plc has announced that it will present clinical data from its phase 1b study of ALKS 2680 for narcolepsy type 2 and idiopathic hypersomnia at the European Sleep Research Society's 27th Congress, Sleep Europe 2024. The data from the narcolepsy type 2 cohort will be shared in an oral presentation, while the data from the idiopathic hypersomnia cohort will be featured in a poster presentation. The event is scheduled for September 2024 in Dublin.

FAQ

  • What is the primary business of Alkermes?
  • What is the ticker symbol for Alkermes?
  • Does Alkermes pay dividends?
  • What sector is Alkermes in?
  • What industry is Alkermes in?
  • What country is Alkermes based in?
  • When did Alkermes go public?
  • Is Alkermes in the S&P 500?
  • Is Alkermes in the NASDAQ 100?
  • Is Alkermes in the Dow Jones?
  • When was Alkermes's last earnings report?
  • When does Alkermes report earnings?
  • Should I buy Alkermes stock now?

What is the primary business of Alkermes?

Alkermes is a biopharmaceutical company that develops innovative medicines for mental health and addiction. They focus on creating treatments for conditions like schizophrenia, depression, and opioid dependence, aiming to improve patients' lives through effective therapies and advanced drug delivery systems.

What is the ticker symbol for Alkermes?

The ticker symbol for Alkermes is NASDAQ:ALKS

Does Alkermes pay dividends?

No, Alkermes does not pay dividends

What sector is Alkermes in?

Alkermes is in the Healthcare sector

What industry is Alkermes in?

Alkermes is in the Drug Manufacturers - Specialty & Generic industry

What country is Alkermes based in?

Alkermes is headquartered in Ireland

When did Alkermes go public?

Alkermes's initial public offering (IPO) was on 16 July 1991

Is Alkermes in the S&P 500?

No, Alkermes is not included in the S&P 500 index

Is Alkermes in the NASDAQ 100?

No, Alkermes is not included in the NASDAQ 100 index

Is Alkermes in the Dow Jones?

No, Alkermes is not included in the Dow Jones index

When was Alkermes's last earnings report?

Alkermes's most recent earnings report was on 24 October 2024

When does Alkermes report earnings?

The next expected earnings date for Alkermes is 14 February 2025

Should I buy Alkermes stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions